Human PD-1 (Research Grade Pembrolizumab Biosimilar) Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: PD-1

Pembrolizumab is a humanized monoclonal IgG4 kappa PD-1 blocking antibody.  PD-1 (programmed death receptor-1) is expressed on the surface of lymphocytes, and is also considered an immune checkpoint. The binding of the antibody with PD-1 interferes with the interaction with its ligands PD-L1 and PD-L2 preventing the inhibition of TCR-mediated T-cell proliferation.  The inhibition of this PD-1 pathway results in enhanced immunosurveillance and anti-tumor immune response.  The original therapeutic has been approved by the FDA for refractory melanoma, as well as other types of cancers such as non-small cell lung cancer, cervical cancer, head and neck cancer and Hodgkin's lymphoma.

Product Datasheets

Related Research Areas

• B Cell Activation
• B7/CD28 Family
• Co-stimulatory and Co-inhibitory Molecules
• Co-stimulatory Molecules Associated with Tfh Cells
• ITIM/ITAM Immunoreceptors and Related Molecules
• Natural Killer T (NKT) Cells
• Regulatory T Cells (Tregs)
• Search Immune Checkpoint Targets